Search Results - "Korde, L A"

Genetics of breast cancer: a topic in evolution by Shiovitz, S., Korde, L.A.

“…A hereditary predisposition to breast cancer significantly influences screening and follow-up recommendations for high-risk women. However, in patients with a…”
Get full text

Increased prevalence of testicular microlithiasis in men with familial testicular cancer and their relatives by Korde, L A, Premkumar, A, Mueller, C, Rosenberg, P, Soho, C, Bratslavsky, G, Greene, M H

“…Testicular germ cell tumours (TGCT) cluster in families, but responsible genes remain unidentified. The association between testicular microlithiasis (TM) and…”
Get full text

199OLong-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial by Eiger, D, Ponde, N F, Agbor-Tarh, D, Korde, L A, Moreno Aspitia, A, Rodeheffer, R J, Ewer, M, Suter, T, Piccart, M, de Azambuja, E

Get full text

Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial by Eiger, D., Ponde, N.F., Agbor-Tarh, D., Korde, L.A., Moreno Aspitia, A., Rodeheffer, R.J., Ewer, M., Suter, T., Piccart, M., de Azambuja, E.

Get full text

Variants in or near KITLG, BAK1, DMRT1, and TERT-CLPTM1L predispose to familial testicular germ cell tumour by Kratz, Christian P, Han, Summer S, Rosenberg, Philip S, Berndt, Sonja I, Burdett, Laurie, Yeager, Meredith, Korde, Larissa A, Mai, Phuong L, Pfeiffer, Ruth, Greene, Mark H

“…Familial testicular germ cell tumours (TGCTs) and bilateral TGCTs comprise 1-2% and 5% of all TGCTs, respectively, but their genetic basis remains largely…”
Get more information

Assessing breast cancer risk: Genetic factors are not the whole story by Korde, Larissa A., Calzone, Kathleen A., Zujewski, JoAnne

“…Genetic syndromes that convey a significant risk of breast cancer are responsible for a small but significant percentage of these cancers. However, the vast…”
Get full text

Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations by Korde, Larissa A, Zujewski, Jo Anne, Kamin, Leah, Giordano, Sharon, Domchek, Susan, Anderson, William F, Bartlett, John M S, Gelmon, Karen, Nahleh, Zeina, Bergh, Jonas, Cutuli, Bruno, Pruneri, Giancarlo, McCaskill-Stevens, Worta, Gralow, Julie, Hortobagyi, Gabriel, Cardoso, Fatima

“…Male breast cancer is a rare disease, accounting for less than 1% of all breast cancer diagnoses worldwide. Most data on male breast cancer comes from small…”
Get full text

Abstract P5-15-03: Bisphosphonate use and breast cancer recurrence risk in the QUILT cohort by Korde, LA, Doody, DR, Malone, KE

“…Background: Women with breast cancer are often prescribed bisphosphonates (BP) for treatment or prevention of osteoporosis. Clinical trials designed to assess…”
Get full text

Bisphosphonate Use and Risk of Recurrence, Second Primary Breast Cancer, and Breast Cancer Mortality in a Population-Based Cohort of Breast Cancer Patients by Korde, Larissa A, Doody, David R, Hsu, Li, Porter, Peggy L, Malone, Kathleen E

“…Studies of bisphosphonate use and breast cancer recurrence have produced conflicting results. Analyses of large adjuvant trials suggest that bisphosphonates…”
Get full text

Increased prevalence oftesticular microlithiasis in men with familial testicular cancer and their relatives by KORDE, L. A, PREMKUMAR, A, MUELLER, C, ROSENBERG, P, SOHO, C, BRATSLAVSKY, G, GREENE, M. H

Get full text

Abstract P2-08-14: Dissecting the effect of hormone receptor (HR) status expression in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Exploratory analysis from the ALTTO (BIG 2-06) trial by Lambertini, M, Campbell, C, Gelber, RD, Viale, G, McCullough, A, Tonghua, L, Hilbers, F, Korde, LA, Werner, O, Chumsri, S, Jackisch, C, Wolff, AC, Vaz-Luis, I, Ferreira, AR, Prat, A, Moreno Aspitia, A, Piccart, M, Loi, S, de Azambuja, E

“…Background We investigated the clinical outcomes and behavior of HER2+ EBC according to centrally tested HR status in pts treated with modern chemotherapy (CT)…”
Get full text

Testicular ultrasound (TU) screening in men from familial testicular cancer (FTC) kindreds by Korde, L. A., Premkumar, A., Kramer, J. L., Linehan, W., Pfeiffer, S., Bratslavsky, G., Greene, M. H.

“…Abstract only 14547 Background: A family history of testicular cancer (TC) is associated with a 2- to 10-fold increase in TC risk. Specific abnormalities of…”
Get full text

Abstract P4-22-11: Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib by Specht, JM, Gadi, VK, Gralow, JR, Korde, LA, Linden, HM, Salazar, LG, Rodler, ET, Cundy, A, Buening, BJ, Baker, KK, Redman, MW, Kurland, BF, Garrison, MA, Smith, JC, vanHaelst, C, Anderson, JE

“…Background: Chemotherapy remains the mainstay of therapy for patients with metastatic triple negative breast cancer (TNBC). We hypothesized that the addition…”
Get full text

Abstract P6-11-02: Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial by Forero, A, Yee, D, Buxton, MB, Symmans, WF, Chien, AJ, Boughey, JC, Elias, AD, DeMichele, A, Moulder, S, Minton, S, Kaplan, HG, Albain, KS, Wallace, AM, Haley, BB, Isaacs, C, Korde, LA, Nanda, R, Lang, JE, Kemmer, KA, Hylton, NM, Paoloni, M, van't Veer, L, Lyandres, J, Perlmutter, J, Hogarth, M, Yau, C, Sanil, A, Berry, DA, Esserman, LJ

“…Background:Pathologic complete response(pCR) after neoadjuvant therapy is an established prognostic biomarker for high-risk breast cancer(BC). Improving pCR…”
Get full text

Abstract P6-11-04: The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial by Yee, D, Paoloni, M, van't Veer, L, Sanil, A, Yau, C, Forero, A, Chien, AJ, Wallace, AM, Moulder, S, Albain, KS, Kaplan, HG, Elias, AD, Haley, BB, Boughey, JC, Kemmer, KA, Korde, LA, Isaacs, C, Minton, S, Nanda, R, DeMichele, A, Lang, JE, Buxton, MB, Hylton, NM, Symmans, WF, Lyandres, J, Hogarth, M, Perlmutter, J, Esserman, LJ, Berry, DA

“…Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within biomarker subtypes to evaluate novel agents when added to…”
Get full text

P3-11-06: A Pilot Study of RPFNA in Overweight and Obese Postmenopausal Women by Korde, LA, Grieco, VS, Imayama, I, Kumai, C, Mason, C, Duggan, CR, Wang, C-Y, McTiernan, A

“…Background: Random periareolar fine-needle aspiration (RPFNA) is a research-based procedure used to obtain breast epithelial cells and fluid. Data suggest that…”
Get full text

P1-06-25: Changes in FDG PET SUV Correlates with Ki-67 Following 2 Weeks of Aromatase Inhibitor Therapy in ER+ Early Stage Breast Cancer, a Pilot Imaging Study by Gadi, VK, Kurland, BF, Specht, JM, Rodler, E, Korde, LA, Peterson, LM, Schubert, EK, Chai, X, Mankoff, DA, Linden, HM

“…Background: In estrogen receptor positive (ER+) tumors, a low proliferative index (Ki-67) two weeks into endocrine therapy predicts response. FDG PET…”
Get full text

Breast cancer risk in mutation-negative members of known BRCA1/2 mutation-positive families by Korde, LA, Mueller, CM, Nichols, K, Loud, JT, Struewing, J, Greene, MH, Mai, PL

“…Abstract #1093 Background: Women with deleterious mutations in BRCA1 and BRCA2 have a 40-85% lifetime risk of breast cancer. Female members of BRCA1/2…”
Get full text